^
Association details:
| Biomarker: | PALB2 mutation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Rubraca (rucaparib) (PARP inhibitor) + lucitanib (E 3810) (FGFR inhibitor, VEGFR inhibitor, Tyrosine kinase inhibitor, PDGFR α-β inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.
Published date:
05/19/2021
Excerpt:
Rucaparib and lucitanib were escalated using a 3+3 phase 1b dose-escalation design from starting doses of 300 mg BID and 4 mg QD, respectively. Dose-limiting toxicities (DLTs) were assessed during the first 28 days of treatment….1 patient in Cohort 1 with PALB2-mutated advanced endometrial cancer had a confirmed partial response...
DOI:
10.1200/JCO.2021.39.15_suppl.3102
Trial ID:
